Modified Vaccine for High Risk or Low Residual Melanoma Patients
Modified Vaccine for High Risk or Low Residual Melanoma Patients
Recruiting · NCT01898039 · Registry updated 2025-10-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Modified Vaccine for High Risk or Low Residual Melanoma Patients | Neoplasm, Residual, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-10-02 | NCT01898039 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hadassah Medical Organization | 53 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Sharett Institute of Oncology, Hadassah Medical Organization | Jerusalem | Israel | 1 |